Compare NTRA & NOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTRA | NOK |
|---|---|---|
| Founded | 2003 | 1865 |
| Country | United States | Finland |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Radio And Television Broadcasting And Communications Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.9B | 36.1B |
| IPO Year | 2015 | N/A |
| Metric | NTRA | NOK |
|---|---|---|
| Price | $231.21 | $6.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 2 |
| Target Price | ★ $249.53 | $8.00 |
| AVG Volume (30 Days) | 1.1M | ★ 36.5M |
| Earning Date | 02-26-2026 | 01-29-2026 |
| Dividend Yield | N/A | ★ 1.67% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.13 |
| Revenue | $2,116,676,000.00 | ★ $23,352,119,300.00 |
| Revenue This Year | $33.77 | $6.58 |
| Revenue Next Year | $16.92 | $3.98 |
| P/E Ratio | ★ N/A | $46.99 |
| Revenue Growth | ★ 38.17 | 3.48 |
| 52 Week Low | $125.38 | $4.00 |
| 52 Week High | $256.36 | $8.19 |
| Indicator | NTRA | NOK |
|---|---|---|
| Relative Strength Index (RSI) | 44.72 | 46.97 |
| Support Level | $229.14 | $6.06 |
| Resistance Level | $250.00 | $7.09 |
| Average True Range (ATR) | 8.27 | 0.19 |
| MACD | -1.38 | -0.02 |
| Stochastic Oscillator | 21.29 | 35.92 |
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Nokia provides telecom equipment and services that are used to build wireless and fixed-line networks. It operates in four segments. The mobile networks segment sells equipment and services to telecom carriers to power public wireless networks. Network infrastructure focuses on fixed-line networks, including switching and routing equipment, optical components, and devices used in fiber-to-the-premises networks. The cloud and network services segment develops software used to operate the core of carrier wireless networks and build private networks for enterprises. Nokia also has a sizable research and patent business, where it licenses technology used by handset providers, consumer electronics firms, and other firms making electronic and Internet of Things products.